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Introduction {#phy214261-sec-0001}
============

Abnormalities in the gut microbiome are associated with perturbations in systemic immune reaction (Belizario et al., [2018](#phy214261-bib-0002){ref-type="ref"}) and predisposition to atopic disease such as asthma and eczema (Zimmermann et al., [2019](#phy214261-bib-0024){ref-type="ref"}). While several genetic (Sherrill and Rothenberg, [2011](#phy214261-bib-0020){ref-type="ref"}), environmental (Hill and Spergel, [2018](#phy214261-bib-0008){ref-type="ref"}) and esophageal microbiome (Benitez et al., [2015](#phy214261-bib-0003){ref-type="ref"}; Harris et al., [2015](#phy214261-bib-0007){ref-type="ref"}; Norder Grusell et al., [2018](#phy214261-bib-0017){ref-type="ref"}) factors have been implicated in EoE, there is evidence that supports a role for the gut microbiome. For example, factors associated with altered gut microbiome such as lack of breast feeding and performance of Cesarean section(Jensen et al., [2018](#phy214261-bib-0010){ref-type="ref"}) or early life antibiotic use (Radano et al., [2014](#phy214261-bib-0019){ref-type="ref"}) have been associated with EoE. Multiple studies in human subjects have found an association between altered gut microbiota and atopic disorders (Nimwegen et al., [2011](#phy214261-bib-0016){ref-type="ref"}; Ismail et al., [2012](#phy214261-bib-0009){ref-type="ref"}; Lau et al., [2012](#phy214261-bib-0013){ref-type="ref"}) and impaired mucosal barrier function (Katzka et al., [2014](#phy214261-bib-0011){ref-type="ref"}; Sherrill et al., [2014](#phy214261-bib-0021){ref-type="ref"}) in response to circulating cytokines (Sherrill et al., [2014](#phy214261-bib-0021){ref-type="ref"}). The sensitization to food antigens triggering an immune response and driving esophageal inflammation in EoE (Noti et al., ([2013](#phy214261-bib-0018){ref-type="ref"})) also suggests a role for gut microbes as commensal bacteria within C*lostridium* clusters XIVa, XIVb, and IV have previously been described to protect against development of food allergies in rodent studies by driving expansion of FoxP3 + regulatory T cells (Tregs) and improving barrier function (Stefka et al., [2014](#phy214261-bib-0022){ref-type="ref"}). Finally the positive response to elemental diet seen in EoE (Kelly et al., [1995](#phy214261-bib-0012){ref-type="ref"}; Markowitz et al., [2003](#phy214261-bib-0014){ref-type="ref"}; Warners et al., [2017](#phy214261-bib-0023){ref-type="ref"}) with its potential effects on stool microbiota{Kajiura, 2009 \#17869}points to role for gut microbiome. Hence in this study we evaluated the gut microbiome represented in the stool from patients with EoE and compared it with matched healthy controls.

Methods {#phy214261-sec-0002}
=======

Ethical approval of human studies {#phy214261-sec-0003}
---------------------------------

All human studies were approved by the Mayo Clinic IRB \[EoE (16‐001097), healthy controls (14‐003005, 16‐006388)\].

Patients {#phy214261-sec-0004}
--------

Adult patients with eosinophilic esophagitis defined by consensus criteria (Dellon et al., [2013](#phy214261-bib-0006){ref-type="ref"}) were sequentially recruited from our eosinophilic esophagitis outpatient clinic. Patients were excluded if they were on proton pump inhibitors, had antibiotic exposure or systemic steroids within the past 2 months. Patients mailed the stool sample in a cold pack within 1 week of endoscopy which was then stored in −80°C till further processing. Healthy adult control patients were recruited as part of different studies and matched with the EoE patients for age, sex and BMI. None of the healthy controls had history of asthma, antibiotic use within past 4 weeks or PPI use. Only one control was delivered by C‐section and no controls had early life antibiotic exposure. All were on a regular diet.

Microbiome analysis {#phy214261-sec-0005}
-------------------

Stool bacterial DNA was extracted using MoBio fecal DNA extraction kit, followed by 16S rRNA amplification using Nextera library compatible primers flanking the V4 hypervariable region (\[forward overhang\] + 515F: \[TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG\]GTGCCAGCMGCCGCGGTAA; and \[reverse overhang\] + 806R: \[GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG\]GGACTACHVGGGTWTCTAAT) and prepared for sequencing using a dual‐indexing protocol. All samples were sequenced together in 2x300 paired‐end mode on an Illumina MiSeq instrument using v3 reagents by the University of Minnesota Genomics Center. Paired R1 and R2 sequence reads were processed via the *hybrid‐denovo* bioinformatics pipeline (Chen et al., [2018](#phy214261-bib-0005){ref-type="ref"}), which clustered good‐quality paired and single‐end reads into operational taxonomic units (OTUs) at 97% similarity level. In total, 989,199 reads (median: 41,727 reads per sample, range: 21,861 to 53,839 reads per sample) were included. OTUs were assigned taxonomy using RDP classifier trained on the Silva database (v132). These OTUs belong to 15 phyla, 84 families, and 248 genera.

Alpha‐diversity (species richness (observed number of OTU) and Shannon index) and beta‐diversity (unweighted, generalized (*α* = 0.5), and weighted UniFrac and Bray‐Curtis distance) were analyzed for the OTU data (R "GUniFrac" package v1.1; Chen et al., [2012](#phy214261-bib-0004){ref-type="ref"}). Rarefaction was performed on the OTU table for the diversity analyses (rarefied to 20,000 reads per sample). A linear regression model (*t*‐test) was used for testing the association with alpha‐diversity. Beta‐diversity association was tested using PERMANOVA based on the aforementioned distance measures. Taxa‐level association analyses were performed at multiple taxonomic levels. The count data were normalized by GMPR size factor to address potential compositional effects. Taxa with prevalence less than 10% or with a maximum proportion less than 0.2% were excluded. A permutation test (1000 permutations) was used to identify differentially abundant taxa based on the t‐statistic of a linear regression model with the square‐root transformed taxa relative abundance as the response variable. Permutation‐based false discovery rate (FDR) control was used to correct for multiple testing on each taxonomic level, and FDR‐adjusted p‐values or *q*‐values ≤ 0.1 were considered significant. All statistical analyses were performed in R 3.4.2.

Results {#phy214261-sec-0006}
=======

Twelve patients with eosinophilic esophagitis (eight active) had a median age of 48 (34‐64), body mass index (BMI) was 29.51 (22.40--36.49), four were male and all were Caucasian (Table [1](#phy214261-tbl-0001){ref-type="table"}). Only one patient had asthma and one had atopic dermatitis. Six patients were on a regular diet. No patients were on PPIs. The healthy control patients had a median age 51 (33--61), BMI 24.75 (19.73--41.39), three were male and all were Caucasian. None had a history of asthma, atopic dermatitis, or PPI use.

###### 

Clinical and demographic characteristics of study patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                 Age   Gender            Allergies    Asthma   atopic dermatitis   Delivered by C‐section   Hx of antibiotics \< 1 year old   Breast feed                Meds                    EoE Diet therapy
  -------------- ----- ----------------- ------------ -------- ------------------- ------------------------ --------------------------------- -------------------------- ----------------------- ------------------
  Active EoE     34    F                 Seasonal,\   Yes      No                  Yes                      No                                No                         albuterol               Yes
                                         Dogs/cats                                                                                                                                               

  42             M     Seasonal          No           No       No                  Yes                      No                                Albuterol\                 No                      
                                                                                                                                              Flonase                                            

  44             F     None              No           No       No                  No                       No                                Multivitamin               No                      

  49             F     Seasonal          No           No       No                  No                       Yes                               Synthroid, Lisinophril     Yes                     

  53             F     None              No           No       No                  No                       UNK                               Adderall\                  No                      
                                                                                                                                              Flonase                                            

  54             F     None              No           No       No                  No                       UNK                               Norvasc\                   No                      
                                                                                                                                              Neurontin, Wellbutrin‐XL                           

  58             M     Cat dander        No           No       No                  No                       UNK                               Afrin\                     No                      
                                                                                                                                              Lipitor                                            

  64             M     MSG, bee stings   No           No       No                  No                       No                                Flovent\                   No                      
                                                                                                                                              Zantac                                             

  Inactive EoE   37    F                 None         No       No                  No                       No                                Yes                        Allegra, montelukast\   Yes
                                                                                                                                                                         Zantac                  

  46             F     None              No           No       No                  No                       No                                Zoloft                     Yes                     

  46             F     Animals/dust      No           No       No                  No                       No                                Budesonide                 No                      

  52             M     Seasonal/animal   No           Yes      UNK                 UNK                      UNK                               Sidenafil\                 Yes                     
                                                                                                                                              Synthroid                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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We compared the 16S rRNA‐based microbial community composition in stool samples from the patients with EoE (*n* = 12) and healthy control subjects (*n* = 12). At the phylum level, we observed a marked decrease in Firmicutes and increase in Bacteroidetes in patients with EoE (Fig. [1](#phy214261-fig-0001){ref-type="fig"}A). The gut microbial communities from patients with EoE were characterized by a lower alpha diversity (species richness, *P = 0.09*; Shannon index, *P* = 0.01; linear regression; Fig. [1](#phy214261-fig-0001){ref-type="fig"}B, [1](#phy214261-fig-0001){ref-type="fig"}). The beta‐diversity was also significantly different between patients with EoE and healthy controls (*P* = 0.03, PERMANOVA based on weighted UniFrac; *P* = 0.04, omninbus test combining multiple beta diversity measures; Fig. [1](#phy214261-fig-0001){ref-type="fig"}D). There were significant differences in relative abundance at multiple taxonomic levels when comparing the two communities, which included significant decreases in *Clostridia* and *Clostridiales* in patients with EoE (*q* ≤ 0.1, permutation test with t‐statistic; Fig. [1](#phy214261-fig-0001){ref-type="fig"}E**)**.

![The phylum‐level profiles (A), alpha diversity (within subject) based on species richness (B) and Shannon index (C), principal coordinate analysis (PCoA) plot showing beta diversity based on weighted UniFrac (D), and barplot comparing the abundance of Clostridia/*Clostridiales* (E) among healthy controls (*n* = 12) and EoE patients (*n* = 12).](PHY2-7-e14261-g001){#phy214261-fig-0001}

Discussion {#phy214261-sec-0007}
==========

In our pilot study we found significant differences in microbial community structure and a decrease in microbial richness and evenness in patients with EoE. Additionally we found a significant decrease in taxa within the Clostridia in patients with EoE. In the differential abundance analysis, we used a permutation test based on the normalized and transformed data, thus, the observed difference in Clostridia was less likely to be driven by sequence depth variation and outliers. In fact, similar *P*‐values were obtained even if we rarefied the data to 20,000 reads per sample. This finding is particularly important as previous studies show that members of *Clostridia* group are protective against the development of food allergies in a rodent model. *Clostridia*‐containing microbiota was associated with the expansion of intestinal regulatory T cells (Treg), induction of IL‐22 production by RORγt^+^ ILCs and class switching to IgA promoting an immune environment conducive for tolerance to dietary antigens (Stefka et al., [2014](#phy214261-bib-0022){ref-type="ref"}). The abundance of *Clostridiales* correlated with the expression of antimicrobial peptide *Reg3b* suggesting *Reg3b* may play a role in modulating the abundance of Cl*ostridiales* in the colon (Stefka et al., [2014](#phy214261-bib-0022){ref-type="ref"}). In addition to rodent studies, *Clostridia* strains isolated from healthy human feces have also been shown to induce Tregs in colonic lamina propria when transferred to germ‐free mice (Nagano et al., [2012](#phy214261-bib-0015){ref-type="ref"}).

Our study is limited by the small sample size although the ability to show significant differences given the number of variables in study of the microbiome is noteworthy. Strengths of the study are a lack of medications, such as proton pump inhibitors (Bajaj et al., [2018](#phy214261-bib-0001){ref-type="ref"}), or other atopic illnesses in most patients that have been associated with altered stool microbiome. This is difficult to achieve as most patients with atopic illness associated with microbiome differences commonly have other atopic conditions and/or usage of medications for these diseases. Furthermore, we limited our analyses to stool samples as we were interested in the association of an altered gut microbiome rather than the esophageal microbiome as a change in the former has been reported to predispose to organ specific atopic disorders, such as asthma, later in life. On the other hand, we cannot precisely identify the relationship of early life changes in stool microbiome to what is found in these patients as adults. Finally, whether our data support the use of Clostridia based interventions as adjuncts to current therapeutic strategies in EoE needs to be further assessed.
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###### 

**Figure S1**: Proposed pathogenesis of microbiome in eosinophilic esophagitis.
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Click here for additional data file.
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